Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776313 | 0.87 | NAMPT (0.40) | NAMPTHCRTR2TYRO3 | |
| SCHEMBL16776327 | 0.83 | RPS6KA2 (0.39) | IRAK4RPS6KA2KARS1 | |
| SCHEMBL16776354 | 0.79 | RPS6KA2 (0.39) | RPS6KA2KARS1 | |
| SCHEMBL16775850 | 0.78 | FGFR4 (0.44) | CSF1RRPS6KA2HCRTR2 | |
| SCHEMBL16776022 | 0.77 | RPS6KA2 (0.41) | RPS6KA2 | |
| SCHEMBL16775855 | 0.77 | CA9 (0.39) | RPS6KA2KARS1 | |
| SCHEMBL16776092 | 0.76 | FGFR4 (0.44) | CSF1RIRAK4RPS6KA2KITPDGFRA | |
| SCHEMBL16775921 | 0.76 | FGFR4 (0.37) | RPS6KA2 | |
| SCHEMBL16776144 | 0.74 | KMT2A (0.44) | RPS6KA2 | |
| SCHEMBL16776011 | 0.74 | CA9 (0.38) | RPS6KA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | NAMPT 74/4885PIM1 2799/4885CSF1R 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.